OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Japan

Phase 3, randomised, double-blind trial of botulinum toxin type A (4 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants who Achieve 'None' or 'Mild' on Facial Wrinkle Scale with Asian Photonumeric Guide According to the Investigator Assessment of Forehead Lines Severity at Maximum Contraction at 30 days and Number of Participants with Adverse Events at 12 months. Started Jan 2025; status: completed.